Cargando…
Bortezomib treatment for severe refractory anti‐NMDA receptor encephalitis
OBJECTIVE: To evaluate the therapeutic potential of bortezomib, a proteasome inhibitor that target plasma cells, in order to revive stalled recovery in patients with anti‐N‐methyl‐d‐aspartate (NMDA) receptor encephalitis who remain bedridden even after aggressive immunotherapy. METHODS: We consecuti...
Autores principales: | Shin, Yong‐Won, Lee, Soon‐Tae, Kim, Tae‐Joon, Jun, Jin‐Sun, Chu, Kon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945964/ https://www.ncbi.nlm.nih.gov/pubmed/29761122 http://dx.doi.org/10.1002/acn3.557 |
Ejemplares similares
-
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis
por: Turnbull, Marion T., et al.
Publicado: (2020) -
Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis
por: Jun, Jin‐Sun, et al.
Publicado: (2017) -
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
por: Ratuszny, Dominica, et al.
Publicado: (2020) -
Anti-NMDA Receptor Encephalitis in a Pregnant Woman
por: Kim, Jiyoung, et al.
Publicado: (2015) -
Anti-NMDA Receptor Encephalitis and Vaccination
por: Wang, Hsiuying
Publicado: (2017)